Text/Picture Yangcheng Evening News All-Media Reporter Zhang Hua
html On August 20, the "Report on the Survival Status of Chinese Patients with Inoperable Esophageal Squamous Carcinoma after Radiotherapy" (hereinafter referred to as the "Report") was officially released. The report was jointly led by Professor Wang Lvhua, Dean of the Shenzhen Hospital of the Cancer Hospital of the Chinese Academy of Medical Sciences, and Professor Zhao Kaixin, Director of the Chest Department of the Radiotherapy Center of the Cancer Hospital of Fudan University. It was also led by Wang Xin, deputy chief physician of the Radiotherapy Department of the Cancer Hospital of the Chinese Academy of Medical Sciences. As the executive secretary, the professor is supported by 15 clinical experts from 14 provincial hospitals across the country.
14 radiotherapy centers provide real-world data on more than 3,000 patients
Esophageal cancer is a common tumor in my country, with the highest incidence and mortality rate in the world. More than half. Professor Wang Lvhua said in an interview with reporters that most of the patients diagnosed with esophageal cancer in my country are in the middle and late stages, and a large proportion of inoperable patients are inoperable. Therefore, radiotherapy plays an important role as an important means of treatment for this type of patients. However, in clinical practice, due to low awareness of radiotherapy, this important treatment method was often ignored or forgotten in the past.
This survey is the first in my country so far and also has the largest sample size. The survey involves more than 5 years of follow-up for patients with esophageal cancer who were not treated with immunological drugs after radical concurrent chemoradiotherapy in multiple medical centers across China. The report is comprehensive, including not only survival conditions, but also analysis of the impact of radiotherapy technology on survival. As well as follow-up consultations after radiotherapy and medical treatment across provinces, etc., special emphasis was placed on investigating the quality of life of long-term survival patients after radiotherapy. Professor Wang Lvhua said, "The survey lasted for nearly a year in 14 units across the country, and 3,060 patients were included in the analysis. This summary summarized the real survival situation of patients with inoperable esophageal squamous cell carcinoma from 2015 to 2016, which is very precious."
Radiotherapy patients The five-year survival rate of and reached 30.0%
According to the "Report", 2015-2016 The overall 5-year survival rate for patients who received radical chemoradiotherapy (without immunotherapy) was 30%. Professor Zhao Kailuo said that with the passage of time, the 5-year survival rate after radiotherapy for esophageal cancer has increased from 10% in the 1980s and 1990s, to 20% in the early 21st century, to 30% in this survey, to 30% in the past two years. 40% of reports. This fully demonstrates that radiotherapy is one of the radical treatments for esophageal cancer. With the advancement of radiotherapy technology and the rapid development of new chemotherapy and immunological drugs, the cure rate of esophageal cancer radiotherapy is constantly improving.
In the treatment of esophageal cancer, patients are still confused about whether to choose surgical treatment or radiotherapy. Most patients prefer surgical treatment. Professor Wang Xin said that in recent years, more and more studies have shown that patients with esophageal cancer who are well treated by radiotherapy do not need to undergo surgical resection and can achieve the same effect as surgery. The biggest advantage of radiotherapy in the treatment of esophageal cancer is to preserve esophageal function. Especially for upper or cervical esophageal cancer with higher tumor location, surgery requires total laryngectomy, while radiotherapy can preserve laryngeal function.
Among the surviving patients, more than half have returned to normal life.
The "Report" shows that about 70%-80% of esophageal cancer patients who have survived long-term after radiotherapy are satisfied or quite satisfied with the quality of life and are full of confidence in fighting the disease. And more than half of patients can return to normal work and life after radiotherapy. This shows that radiotherapy is a promising treatment strategy.
It is noteworthy that the "Report" also pointed out that the survival conditions of patients with different radiotherapy techniques and different radiotherapy and chemotherapy regimens are significantly different. Professor Zhao Kaixin believes that the main reason for this situation is that the number of cancer patients has been increasing in recent years, but the domestic shortage of radiotherapy equipment and radiotherapy experts has led to far insufficient use of radiotherapy. Many patients do not have the opportunity to receive radiotherapy and do not understand radiotherapy. What is it? This situation is particularly prominent in economically underdeveloped areas. The National Cancer Center has issued radiotherapy quality control guidelines in 2017, urging all units to implement strict quality control standards, which will play a major role in improving the accuracy of radiotherapy and promoting industry standardization.In addition, the wide application of 5G has promoted the development of remote radiotherapy technology, which can bring the same high-quality radiotherapy resources to more areas lacking resources and bring benefits to more cancer patients.
There are more "new weapons" in the treatment of esophageal cancer
This "Report" also discussed the application of immunotherapy . Professor Zhao Kaixin said that with the rise of innovative treatments such as immunotherapy, esophageal cancer Cancer treatment not only has more "new weapons", but also triggers more exploration and discussion of new treatment concepts such as precision immunity and radiotherapy combined with immunity.
It is reported that in 2020, China’s first esophageal cancer immunotherapy drug pembrolizumab was approved. In the 2022 "CSCO Esophageal Cancer Diagnosis and Treatment Guidelines", the first-line treatment regimen of pembrolizumab combined with chemotherapy for advanced esophageal cancer is also regarded as the highest level I recommendation, establishing this therapy as a new standard treatment for first-line patients with advanced esophageal cancer.
Professor Wang Lvhua said that with the widespread application of immunotherapy, radiotherapy clinicians, experts and scholars are also actively adapting to the development of the times. The report released this time mainly focuses on radiotherapy patients who have not used immunotherapy between 2015 and 2016. Currently, we are also conducting research on radiotherapy patients who have used immunotherapy, and we hope to further reflect on innovative treatment methods such as combined radiotherapy. , can prolong the patient's survival time and improve the patient's quality of life. (For more news and information, please follow Yangcheng Pai pai.ycwb.com)
Source | Yangcheng Evening News·Yangcheng Pai
Editor | Niu Zhijie
